2,305
Views
5
CrossRef citations to date
0
Altmetric
Coronavirus – Research Paper

The COVID-19 vaccine concerns scale: Development and validation of a new measure

, , ORCID Icon, , ORCID Icon, , ORCID Icon & show all
Article: 2050105 | Received 26 Oct 2021, Accepted 02 Mar 2022, Published online: 05 Apr 2022

References

  • Centers for Disease Control and Prevention. Benefits of getting a COVID-19 vaccine. CDC; 2022 Jan 11 [accessed 2022 Jan 31]. http://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html
  • Centers for Disease Control and Prevention. COVID-19 vaccinations in the United States. 2021 Sept 15 [ accessed 2021 Sept 15]. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total
  • Solis Arce J, Warren S, Meriggi N, Scacco A, McMurry N, Voors M, Syunyaev G, Malik A, Aboutajdine S, Omer S. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nat Med. 2021;27(8):1385–7. doi:10.1038/s41591-021-01454-y.
  • Edwards B, Biddle N, Gray M, Sollis K. COVID-19 vaccine hesitancy and resistance: correlates in a nationally representative longitudinal survey of the Australian population. PLOS One. 2021;16(3):e0248892. doi:10.1371/journal.pone.0248892.
  • Raciborski F, Samel-Kowalik P, Gujski M, Pinkas J, Arcimowicz M, Jankowski M. Factors associated with a lack of willingness to vaccinate against COVID-19 in Poland: a 2021 nationwide cross-sectional survey. Vaccines. 2021;9(9):1–11. doi:10.3390/vaccines9091000.
  • Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 vaccine hesitancy and its associated factors in Japan. Vaccines. 2021;9(6):662. doi:10.3390/vaccines9060662.
  • Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–94. doi:10.1056/NEJMoa2108891.
  • Centers for Disease Control and Prevention. Delta variant: what we know about the science. CDC; 2021 Aug 21 [accessed 2022 Jan 31]. https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
  • Centers for Disease Control and Prevention. Joint statement from HHS Public Health and medical experts on COVID-19 booster shots. CDC; 2021 Aug 18 [accessed 2022 Jan 31]. https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html
  • Centers for Disease Control and Prevention. Who is eligible for a COVID-19 vaccine booster shot? CDC; 2022 Jan 21 [accessed 2022 Jan 31]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
  • Shivaram D. Why Pfizer’s FDA approval matters and what it means for vaccine mandates. NPR; 2021 Aug 24 [accessed 2022 Aug 24]. https://www.npr.org/sections/coronavirus-live-updates/2021/08/24/1030267314/pfizer-vaccine-covid-fda-approval-kids-faq-mandate
  • Cowan S, Mark N, Reich J. COVID-19 vaccine hesitancy is the new terrain for political division among Americans. Socius. 2021;7:1–3. doi:10.1177/23780231211023657.
  • Razai M, Chaudhry U, Doerholt K, Bauld L, Majeed A. COVID-19 vaccination hesitancy. Bmj. 2021;373:n1138. doi:10.1136/bmj.n1138.
  • Freeman D, Waite F, Rosebrock L, Petit A, Causier C, East A, Jenner L, Teale A, Carr L, Mulhall S, et al. Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. Psychol Med. 2020;21:1–3. doi:10.1017/S0033291720001890.
  • Bertin P, Nera K, Delouvée S. Conspiracy beliefs, rejection of vaccination, and support for hydroxychloroquine: a conceptual replication-extension in the COVID-19 pandemic context. Front Psychol. 2020;11:565128. doi:10.3389/fpsyg.2020.565128.
  • Freeman D, Loe B, Chadwick A, Vaccari C, Waite F, Rosebrock L, Jenner L, Petit A, Lewandowsky S, Vanderslott S, et al. COVID-19 vaccine hesitancy in the UK: the Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS ii). Psychol Med. 2020;11:1–5. doi:10.1017/S0033291720005188.
  • Rodriguez V, Alcaide M, Salazar A, Montgomerie E, Maddalon M, Jones D. Psychometric properties of a vaccine hesitancy scale adapted for COVID‑19 vaccination among people with HIV. AIDS Behav. 2022;26(1):96–101. doi:10.1007/s10461-021-03350-5.
  • Kotta I, Kalcza-Janosi K, Szabo K, Eniko Marschalko E. Development and validation of the multidimensional COVID-19 vaccine hesitancy scale. Hum Vaccin Immunother. 2021; 1–10. Epub ahead of print. doi:10.1080/21645515.2021.2007708.
  • Breslin G, Dempster M, Berry E, Cavanagh M, Armstrong N. COVID-19 vaccine uptake and hesitancy survey in Northern Ireland and Republic of Ireland: Applying the theory of planned behaviour. PLOS One. 2021;16(11):e0259381. doi:10.1371/journal.pone.0259381.
  • Delgado-Gallegos J, Padilla-Rivas G, Zúñiga-Violante E, Avilés-Rodríguez G, Arellanos-Soto D, Gastelum-Arias L, Villareal H, de Los Ángeles Cosío-León M, Romo-Cardenas G, Moreno-Treviño M, et al. Determinants of COVID-19 vaccine hesitancy: a cross-sectional study on a Mexican population using an online questionnaire (COV-AHQ). Front Public Health. 2021;9:728690. doi:10.3389/fpubh.2021.728690.
  • Kumari A, Ranjan P, Chopra S, Kaur D, Upadhyay A, Kaur T, Bhattacharyya A, Arora M, Gupta H, Thrinath A, et al. Development and validation of a questionnaire to assess knowledge, attitude, practices, and concerns regarding COVID-19 vaccination among the general population. Diabetes Metab Syndr. 2021;15(3):919–25. doi:10.1016/j.dsx.2021.04.004.
  • Gregory ME, Powell JR, MacEwan SR, Kurth JD, Kenah E, Panchal AR, McAlearney AS. COVID-19 vaccinations in EMS professionals: prevalence and predictors. Prehosp Emerg Care. 2021; 1–9. Epub ahead of print. doi:10.1080/10903127.2021.1993391.
  • DeVellis R, Thorpe C. Scale development: theory and applications. 4th. Thousand Oaks (CA): Sage; 2016.
  • Hinkin T. A brief tutorial on the development of measures for use in survey questionnaires. Organ Res Methods. 1998;1(1):104–21. doi:10.1177/109442819800100106.
  • Shapiro GK, Tatar O, Dube E, Amsel R, Knauper B, Naz A, Perez S, Rosberger Z. The vaccine hesitancy scale: psychometric properties and validation. Vaccine. 2018;36(5):660–67. doi:10.1016/j.vaccine.2017.12.043.
  • Shapiro GK, Holding A, Perez S, Amsel R, Rosberger Z. Validation of the vaccine conspiracy beliefs scale. Papillomavirus Res. 2016;2:167–72. doi:10.1016/j.pvr.2016.09.001.
  • Zingg A, Siergrist M. Measuring people’s knowledge about vaccination: developing a one-dimensional scale. Vaccine. 2012;30(25):3771–77. doi:10.1016/j.vaccine.2012.03.014.
  • Sarathchandra D, Navin MC, Largent MA, McCright AM. A survey instrument for measuring vaccine acceptance. Preventative Med. 2018;109:1–7. doi:10.1016/j.ypmed.2018.01.006.
  • Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;21(45):7002–06. doi:10.1016/j.vaccine.2020.09.041.
  • Dillman D, Smyth J, Christian L. Internet, phone, mail, and mixed-mode surveys: the tailored design method. 4th. Hoboken (NJ): John Wiley & Sons; 2014.
  • IBM. SPSS Statistics for Macintosh. Ver. 27.0 [software]. Armonk (NY): IBM; 2020.
  • Jöreskog K, Sörbom D. LISREL 10 for Windows. Ver. 10.3.3.26 [software]. Skokie (IL): Scientific Software International, Inc.; 2018.
  • Taber C. The use of Cronbach’s alpha when developing and reporting research instruments in science education. Res Sci Educ. 2018;48(6):1273–96. doi:10.1007/s11165-016-9602-2.
  • Dziuban C, Shirkey E. When is a correlation matrix appropriate for factor analysis? Some decision rules. Psychol Bull. 1974;81(6):358–61. doi:10.1037/h0036316.
  • Yong A, Pearce S. A beginner’s guide to factor analysis: focusing on exploratory factor analysis. Tutor Quant Methods Psychol. 2013;9(2):79–94. doi:10.20982/tqmp.09.2.p079.
  • Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Modeling. 1999;6(1):1–55. doi:10.1080/10705519909540118.
  • Akel K, Masters N, Shih S, Lu Y, Wagner A. Modification of a vaccine hesitancy scale for use in adult vaccinations in the United States and China. Hum Vaccin Immunother. 2021;17(8):2639–46. doi:10.1080/21645515.2021.1884476.
  • Larson H, Jarrett C, Schulz W, Chaudhuri M, Zhou Y, Dube E, Schuster M, MacDonald N, Wilson R. Measuring vaccine hesitancy: the development of a survey tool. Vaccine. 2015;33(34):4165–75. doi:10.1016/j.vaccine.2015.04.037.
  • Ebrahimi O, Johnson M, Ebling S, Amundsen O, Halsøy Ø, Hoffart A, Skjerdingstad N, Johnson S. Risk, trust, and flawed assumptions: vaccine hesitancy during the COVID-19 pandemic. Front Public Health. 2021;9. doi:10.3389/fpubh.2021.700213.
  • Treisman R. Biden says all adults will be vaccine eligible by April 19. NPR; 2021 Apr 6 [accessed 2022 Apr 6]. https://www.npr.org/sections/coronavirus-live-updates/2021/04/06/984745020/biden-will-direct-states-to-make-all-adults-vaccine-eligible-by-april-19
  • Crowe R, Krebs W, Cash R, Rivard M, Lincoln E, Panchal A. Females and minority racial/ethnic groups remain underrepresented in emergency medical services: a ten-year assessment, 2008-2017. Prehosp Emerg Care. 2019;24(2):180–87. doi:10.1080/10903127.2019.1634167.
  • Schmuhl P, Van Duker H, Gurley K, Webster A, Olson L. Reaching emergency medical services providers: is one survey mode better than another? Prehosp Emerg Care. 2010;14(3):361–69. doi:10.3109/10903121003760184.
  • Cash R, Rivard M, Camargo C, Powell J, Panchal A. Emergency medical services personnel awareness and training about personal protective equipment during the COVID-19 pandemic. Prehosp Emerg Care. 2021;25(6):777–84. doi:10.1080/10903127.2020.1853858.